Eli Lilly and Company (NYSE:LLY) is one of the 13 Best Low Risk High Growth Stocks to Buy. Amid carrying on new studies, the ...

Demand for glucagon-like peptide-1 weight-loss drugs — such as Ozempic, Zepbound and Wegovy — coupled with limited insurance ...

Teladoc Health is launching a new employee assistance program (EAP) called Wellbound, which it said is designed to promote a ...

Baseline BMI may play a significant role in improving exercise capacity, body weight and BP among patients with HF with ...

Kiran Musunuru, a University of Pennsylvania cardiologist and leading gene-editing researcher, thinks it’s possible. Musunuru cofounded Verve Therapeutics, a company developing a therapy that uses ...

Novo Nordisk sees 65% obesity drug sales growth, forecasts $8.14–$9.59B FY25 free cash flow. Click here to read an analysis ...

Eli Lilly faces a pivotal moment as its stock experiences a slight pullback. Investors are eyeing its upcoming earnings ...

Ozempic and Zepbound are both prescription injections that are part of the GLP-1 drug class. They have different active ...

With increasing global demand for advanced weight loss solutions, Canadian consumers now have a new way to access the recently approved obesity treatment Zepbound. Online pharmacy DutyFreeMeds.com is ...

Eli Lilly is tagging along on actress Kym Whitley’s blockbuster summer in a fresh Zepbound partnership with the “Happy ...

Eli Lilly outpaces Novo in the GLP-1 market with Tirzepatide and emerging blockbusters, signaling future growth. Read more on ...

Some health experts view GLP-1s as a promising option for PCOS, which lacks a standard treatment and affects millions of ...